UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

AstraZeneca Plc is a biopharmaceutical ... of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

AstraZeneca has a heritage in respiratory medicine, but has not produced any new products in the field for some time. Its existing asthma and COPD franchise is made up of Pulmicort (which earned $ ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

respiratory and immunology; and vaccine and immune therapies. Though the sale of COVID-19 products has somewhat disrupted AstraZeneca's revenue growth in recent years, it has generally been strong.

Novo Nordisk (NYSE: NVO) and AstraZeneca ... company's products span the field of oncology -- its most important and lucrative -- rare diseases; cardiovascular, renal, and metabolism; respiratory ...

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have ... “The work we are doing with AstraZeneca developing a respiratory inhaler, with a new near-zero ...